Fabiola Colon-Santiago

Mrs. Fabiola Colon-Santiago


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AÁAshlin Nicole Álvarez-Flores
Ashlin Nicole Álvarez-Flores
Fabiola Colon-SantiagoFabiola Colon-Santiago
Fabiola Colon-Santiago
NHNaiara I Hernández
Naiara I Hernández
Julieness CorreaJulieness Correa
Julieness Correa
SCSamuel Emir Caldero
Samuel Emir Caldero
Eduardo Alvarez-RiveraEduardo Alvarez-Rivera
Eduardo Alvarez-Rivera
Despite the remarkable success of antiretroviral therapy (ART) in suppressing human immunodeficiency virus type 1 (HIV-1) replication, viral persistence remains a major barrier to cure. This persistence is sustained by heterogeneous cellular reservoirs in which viral expression is tightly regulated by host-dependent molecular mechanisms. Beyond the canonical cluster of differentiation 4 (CD4+) T-cell reservoirs, HIV-1 establishes long-lived infection in myeloid cells, glial populations within the central nervous system (CNS), and additional non-canonical cellular niches, each characterized by distinct transcriptional, epigenetic, and immune environments. In this review, we synthesize recent advances in understanding how HIV-1 expression, latency, and reactivation are shaped across diverse susceptible cell types. We highlight cell-type-specific mechanisms governing viral integration, chromatin organization, transcriptional elongation, innate immune sensing, host restriction factors, and cytoskeletal regulation. Particular emphasis is placed on how host signaling pathways and immune microenvironments contribute to reservoir stability and heterogeneity, complicating eradication strategies. We further discuss immunomodulatory approaches that seek to modulate viral expression without exacerbating immune activation. By integrating molecular, cellular, and immunological perspectives, this review provides a framework for understanding HIV-1 persistence as a context-dependent process and underscores the need for cell-type-tailored strategies in HIV cure research.

Verified
Journal Article
Open access
PDF file
Eduardo Alvarez-RiveraEduardo Alvarez-Rivera
Eduardo Alvarez-Rivera
PRPamela Rodriguez-Vega
Pamela Rodriguez-Vega
Fabiola Colon-SantiagoFabiola Colon-Santiago
Fabiola Colon-Santiago
ARArmeliz Romero-Ponce
Armeliz Romero-Ponce
FUFabiola Umpierre-Lebron
Fabiola Umpierre-Lebron
Solianne M. Martínez-JimenezSolianne M. Martínez-Jimenez
Solianne M. Martínez-Jimenez
Stroke has been a topic of extensive research due to its debilitating consequences and high mortality. New findings offer a deeper understanding of specific factors that affect post-stroke recovery and identify therapies that may facilitate this process. One such factor is post-stroke neuroinflammation, a complex and time-dependent process in which acute immune responses can cause significant secondary inflammatory damage if the process is prolonged. Microglia are neuronal immune cells that are highly reactive to cytokines in the neuroenvironment and can, in turn, affect the inflammatory cascades that originate after stroke, making them ideal candidates for immunomodulation in the brain. Many FDA-approved immunotherapies have been found to target distinct inflammatory signaling molecules and responders, including IL-6 inhibitors, IL-13 inhibitors, IL-12/IL-23 inhibitors, B-cell modulators, type I interferon inhibitors, CAR T-cell therapy, calcineurin inhibitors, complement inhibitors, and JAK-STAT pathway inhibitors. The FDA-approved immunotherapies discussed in this review demonstrate potential in modulating the immune response after stroke by targeting key inflammatory pathways involved in secondary brain injury. Future research should focus on defining optimal therapeutic windows, identifying suitable patient populations, determining the most appropriate timing of therapy, and targeting specific immune mechanisms to balance the attenuation of harmful inflammation with the preservation of reparative processes.

7 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Eduardo Alvarez-RiveraEduardo Alvarez-Rivera
Eduardo Alvarez-Rivera
PRPamela Rodriguez-Vega
Pamela Rodriguez-Vega
Fabiola Colon-SantiagoFabiola Colon-Santiago
Fabiola Colon-Santiago
ARArmeliz Romero-Ponce
Armeliz Romero-Ponce
FUFabiola Umpierre-Lebron
Fabiola Umpierre-Lebron
Solianne M. Martínez-JimenezSolianne M. Martínez-Jimenez
Solianne M. Martínez-Jimenez
Stroke has been a topic of extensive research due to its debilitating consequences and high mortality. New findings offer a deeper understanding of specific factors that affect post-stroke recovery and identify therapies that may facilitate this process. One such factor was microglia, neuronal immune cells that are highly reactive to cytokines in the neuroenvironment and can, in turn, affect the inflammatory cascades that originate after stroke, making them ideal candidates for immunomodulation in the brain. Many FDA-approved immunotherapies have been found to target distinct inflammatory signaling molecules and responders, including IL-6 inhibitors, IL-13 inhibitors, IL-12/IL-23 inhibitors, B-cell modulators, Type I interferon inhibitors, CAR T-cell therapy, Calcineurin inhibitors, Complement inhibitors, and JAK-STAT pathway inhibitors. The FDA-approved immunotherapies discussed in this review demonstrate potential in modulating the immune response after stroke by targeting key inflammatory pathways involved in secondary brain injury. Future research should focus on defining optimal therapeutic windows, identifying suitable patient populations, determining the most appropriate timing of therapy, and targeting specific immune mechanisms to balance the attenuation of harmful inflammation with the preservation of reparative processes.

Verified
Journal Article
Open access
PDF file
Glamaris Nicole RosarioGlamaris Nicole Rosario
Glamaris Nicole Rosario
Giovanni Omar Alicea PérezGiovanni Omar Alicea Pérez
Giovanni Omar Alicea Pérez
AÁAshlin Nicole Álvarez-Flores
Ashlin Nicole Álvarez-Flores
NHNaiara I Hernández
Naiara I Hernández
ARAmanda C. Rivera-Payán
Amanda C. Rivera-Payán
Eduardo Alvarez-RiveraEduardo Alvarez-Rivera
Eduardo Alvarez-Rivera
Natural bioactive polysaccharides have been investigated for their ability to modulate antiviral immune responses. Polysaccharide peptide (PSP) from Coriolus versicolor previously restricted human immunodeficiency virus type 1 (HIV-1) entry into monocytic cells through a protein kinase R (PKR)-dependent cytoskeletal mechanism. However, its impact on antiviral signaling in adaptive cluster of differentiation 4 (CD4)+ T-cell models remains incompletely defined. Here, we evaluated concentration- and time-dependent effects of PSP (50–1000 µg/mL) in Jurkat T cells over 3 and 6 days. Cell viability was assessed by MTT, trypan blue exclusion, and viable cell density analysis. Immunoblotting and reverse transcription quantitative polymerase chain reaction (RT-qPCR) were performed to examine Toll-like receptor 4 (TLR4), nuclear factor kappa B (NF-κB), signal transducer and activator of transcription 1 and 2 (STAT1/STAT2), PKR, interferon gamma (IFN-γ), and cofilin-1 signaling. PSP did not induce cytotoxicity at any concentration. Instead, PSP promoted dose- and time-dependent upregulation of intracellular TLR4, PKR, phospho-PKR (Thr446), Cofilin-1, phospho-Cofilin-1 (Ser3), phospho-STAT1 (Tyr701), phospho-STAT2 (Tyr690), phospho-NF-κB (Ser536), and IFN-γ, with amplified responses at Day 6. These changes were paralleled by transcriptional induction of antiviral-associated genes. Collectively, PSP induces coordinated interferon (IFN)-associated and cytoskeletal regulatory signaling in Jurkat T cells without cytotoxicity, providing a mechanistic framework for future evaluation of viral permissiveness and antiviral responses in adaptive immune models.